Clinical Trials Logo

HPV-Related Cervical Carcinoma clinical trials

View clinical trials related to HPV-Related Cervical Carcinoma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06339684 Active, not recruiting - Clinical trials for HPV-Related Cervical Carcinoma

HPV Immunological Markers of Cervical Persistent Infection and Oncogenesis

HPVImmuno
Start date: March 8, 2023
Phase:
Study type: Observational [Patient Registry]

The aim of this observational study is to build an immunological assay to quantify an immunoscore system for clinical practice, which could identify HPV lesions with a risk of persistent cervical infection, which represents the main predictive factor of neoplastic evolution. A pattern of host immunological factors and HPV-related parameters, in order to identify an algorithm of risk stratification and tailoring treatment will be identified. Finally, in patients with HPV infection, a virus specific immunity after vaccination will be quantified, in order to highlight those patients who have the most significant risk of infection persistence.

NCT ID: NCT03260023 Active, not recruiting - Clinical trials for HPV-Related Carcinoma

Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers

Start date: September 11, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The study will consist of two parts : In the phase Ib: safety will be assessed in consecutive cohorts of 3 to 6 patients at increasing doses of TG4001 in combination with avelumab according to a 3+3 design. There will be no intra-patient dose escalation. In the phase II part 1, evaluation of efficacy and further evaluation of safety of the combination of TG4001 and avelumab will be performed in a single arm of patients with recurrent or metastatic HPV-16 positive advanced malignancies. In the phase II part 2, evaluation of efficacy of the combination of TG4001 and avelumab will be performed in a randomized, open-label controlled study comparing TG4001 in combination with avelumab to avelumab alone in patients with HPV-16 positive advanced malignancies. In both phases, tumor response will be evaluated on local assessment using RECIST 1.1. All patients will be followed up until disease progression, death, or unacceptable toxicity, or study withdrawal for any reason, whichever occurs first.